Associated Papers
ctDNA-based liquid biopsy reveals wider mutational profile with therapy resistance and metastasis susceptibility signatures in early-stage breast cancer patients.
Bharde A et al.
The Journal of Liquid Biopsy, 2025
40027235 (PubMed )
Supplement: mmc4.xlsx › Sheet1
Multiplexed assay of variant effect reveals residues of functional importance in the BRCA1 coiled-coil and serine cluster domains.
Nagy G et al.
Plos One, 2023
37917606 (PubMed )
Supplement: pone.0293422.s008.xlsx › Table_S11.ClinVar_Details
Human BRCA pathogenic variants were originated during recent human history.
Li J et al.
Life Science Alliance, 2022
35165121 (PubMed )
Supplement: LSA-2021-01263_TableS2.xlsx › BRCA1
Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
Aref-Eshghi E et al.
Journal of Human Genetics, 2020
Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer.
Rummel S et al.
Breast Cancer Research and Treatment, 2013
BRCA1 mutations in primary breast and ovarian carcinomas.
Futreal PA et al.
Science (new York, N.y.), 1994
Select a paper to view details